News
AMED
90.64
-0.45%
-0.41
Amedisys Price Target Maintained With a $101.00/Share by Cantor Fitzgerald
Dow Jones · 3h ago
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
TipRanks · 5h ago
Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)
TipRanks · 6h ago
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
NASDAQ · 16h ago
Amedisys Inc Releases First-Quarter Supplemental Slides
TipRanks · 20h ago
AMEDISYS INC <AMED.O> Q1 SHR VIEW $1.02 -- LSEG IBES DATA
Reuters · 21h ago
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
NASDAQ · 1d ago
Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?
NASDAQ · 2d ago
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
NASDAQ · 2d ago
Weekly Report: what happened at AMED last week (0415-0419)?
Weekly Report · 3d ago
DOJ case against UnitedHealth could take years to resolve, says BoA
Healthcare M&A DOJ case against UnitedHealth could take years to resolve, says BoA Securities. US Department of Justice could be pursuing a monopolization case against the healthcare company. Former DOJ lawyer says the case could still be in the discovery stage. BofA maintained its buy rating on UnitedHealth Group.
Seeking Alpha · 5d ago
Weekly Report: what happened at AMED last week (0408-0412)?
Weekly Report · 04/15 09:06
Weekly Report: what happened at AMED last week (0401-0405)?
Weekly Report · 04/08 09:06
Weekly Report: what happened at AMED last week (0325-0329)?
Weekly Report · 04/01 09:06
UnitedHealth deal for Amedisys likely to close despite report of DOJ scutiny - analyst
Healthcare M&A UnitedHealth deal for Amedisys likely to close despite report of DOJ scutiny - analyst. UnitedHealth's planned $3.3 billion acquisition of Amedsys is expected to close, according to an RBC analyst. The Justice Department is reportedly considering a lawsuit to block the deal.
Seeking Alpha · 03/25 18:05
Amedisys Price Target Raised to $100.00/Share From $97.00 by RBC Capital
Dow Jones · 03/25 12:17
Amedisys Is Maintained at Outperform by RBC Capital
Dow Jones · 03/25 12:17
RBC Capital Maintains Outperform on Amedisys, Raises Price Target to $100
Benzinga · 03/25 12:06
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amedisys (AMED) and Masimo (MASI)
TipRanks · 03/25 10:40
Weekly Report: what happened at AMED last week (0318-0322)?
Weekly Report · 03/25 09:06
More
Webull provides a variety of real-time AMED stock news. You can receive the latest news about Amedisys Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMED
Amedisys, Inc. is a healthcare service company. The Company is engaged in providing care and support in the home. It delivers clinically distinct care that suits its patients' needs, whether that is home-based recovery and rehabilitation after an operation or injury or care. Its operations involve serving patients across the United States through its three operating divisions: home health, hospice, and high acuity care. Its home health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The home health includes 346 care centers located in 34 states within the United States and the District of Columbia. Its hospice care is designed to provide comfort and support for those who are dealing with a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes.